What is the share price of Dishman Carbogen Amcis Ltd (DCAL) today?
The share price of DCAL as on 5th August 2026 is ₹195.43. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Dishman Carbogen Amcis Ltd (DCAL) share?
The past returns of Dishman Carbogen Amcis Ltd (DCAL) share are- Past 1 week: 6.73%
- Past 1 month: -0.74%
- Past 3 months: 3.85%
- Past 6 months: -8.09%
- Past 1 year: -22.55%
- Past 3 years: 19.44%
- Past 5 years: -3.92%
What are the peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL)?
The peers or stocks similar to Dishman Carbogen Amcis Ltd (DCAL) include:What is the market cap of Dishman Carbogen Amcis Ltd (DCAL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Dishman Carbogen Amcis Ltd (DCAL) is ₹3064.01 Cr as of 5th August 2026.What is the 52 week high and low of Dishman Carbogen Amcis Ltd (DCAL) share?
The 52-week high of Dishman Carbogen Amcis Ltd (DCAL) is ₹321.95 and the 52-week low is ₹128.50.What is the PE and PB ratio of Dishman Carbogen Amcis Ltd (DCAL) stock?
The P/E (price-to-earnings) ratio of Dishman Carbogen Amcis Ltd (DCAL) is 31.44. The P/B (price-to-book) ratio is 0.53.Which sector does Dishman Carbogen Amcis Ltd (DCAL) belong to?
Dishman Carbogen Amcis Ltd (DCAL) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Dishman Carbogen Amcis Ltd (DCAL) shares?
You can directly buy Dishman Carbogen Amcis Ltd (DCAL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Dishman Carbogen Amcis Ltd
DCAL Share Price
NSE₹195.433.82% (+7.19)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
DCAL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
DCAL Performance & Key Metrics
DCAL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.44 | 0.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.94 | 6.01 | 0.52% |
DCAL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
DCAL Company Profile
Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing
DIVISLAB
PE Ratio
86.71
86.71
1Y Return
30.88%
30.88%
Buy Reco %
56.52
56.52
SYNGENE
PE Ratio
51.64
51.64
1Y Return
41.79%
41.79%
Buy Reco %
62.50
62.50
AARTIPHARM
PE Ratio
35.45
35.45
1Y Return
21.44%
21.44%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
37.87
37.87
1Y Return
0.82%
0.82%
Buy Reco %
0.00
0.00
PE Ratio
37.38
37.38
1Y Return
55.73%
55.73%
Buy Reco %
0.00
0.00
DCAL Sentiment Analysis
DCAL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
DCAL Stock Summary · May 2026
Management characterized the quarter as extremely strong, reporting Q4 revenue of INR 851 crore and FY26 revenue of INR 2,932 crore, with full‑year EBITDA margin improving to 19.3%. Leadership emphasized disciplined execution across deleveraging, India scale‑up and tech transfers, ADC co‑investments, procurement savings and digital and lean initiatives to drive long‑term margins, while noting tension between healthy top‑line growth and near‑term margin pressures: CDMO remains the core (~81–83% of revenue) but CDMO margins softened versus prior year due to absence of late Phase‑3 deliveries even as marketable‑molecule margins improved materially; employee and other expenses rose in Q4 partly from a CHF 2.5m pension provision and onerous‑contract charges. Management outlined specific near‑term expectations, including promoter refinancing to lower consolidated quarterly finance costs toward INR 35–40 crore (target net interest ≤ ~INR 70 crore and consolidated ≤ ~INR 100 crore), a path to tax‑rate normalization (around 40% in FY27, declining thereafter) and higher India revenues and profitability in FY27 with continued focus on deleveraging.
DCAL Stock Growth Drivers
DCAL Stock Growth Drivers
7Marked improvement in recent financial performance and profitability
The company delivered one of its strongest quarters and a materially improved full year, with
Robust CDMO and ADC pipeline with growing commercial visibility
The drug substance business hosts a deep pipeline of late‑phase work (more than 10 late‑phase
DCAL Stock Challenges
DCAL Stock Challenges
6Elevated operating costs, one‑off provisions and rising non‑cash charges compressing margins
The quarter showed materially higher operating cost pressure driven by a mix shift and several
CDMO margin and revenue timing volatility driven by dependence on late‑phase deliveries and customer ordering patterns
The CDMO segment experienced a meaningful QoQ/YoY margin decline (EBITDA margin fell to 18.7% from
DCAL Forecast
DCAL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
DCAL
DCAL
Income
Balance Sheet
Cash Flow
Quarterly Normal View
DCAL Income Statement
DCAL Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 657.14 | 661.87 | 525.21 | 795.69 | 690.01 | 724.31 | 732.80 | 660.76 | 726.46 | 867.82 | ||||||||||
Operating & Other expenses | 609.98 | 595.12 | 500.25 | 644.85 | 542.21 | 575.40 | 570.02 | 503.76 | 606.69 | 689.60 | ||||||||||
EBITDA | 47.16 | 66.75 | 24.96 | 150.84 | 147.80 | 148.91 | 162.78 | 157.00 | 119.77 | 178.22 | ||||||||||
| Depreciation/Amortization | 80.37 | 85.00 | 70.59 | 72.09 | 71.97 | 79.09 | 81.35 | 84.13 | 84.42 | 88.79 | ||||||||||
| PBIT | -33.21 | -18.25 | -45.63 | 78.75 | 75.83 | 69.82 | 81.43 | 72.87 | 35.35 | 89.43 | ||||||||||
| Interest & Other Items | 33.08 | 30.95 | 31.93 | 36.63 | 48.78 | 42.12 | 42.76 | 42.33 | 45.79 | 43.30 | ||||||||||
| PBT | -66.29 | -49.20 | -77.56 | 42.12 | 27.05 | 27.70 | 38.67 | 30.54 | -10.44 | 46.13 | ||||||||||
| Taxes & Other Items | -6.66 | 20.72 | 0.01 | 9.03 | 22.42 | -15.39 | 15.26 | -34.73 | 2.53 | 24.39 | ||||||||||
| Net Income | -59.63 | -69.92 | -77.57 | 33.09 | 4.63 | 43.09 | 23.41 | 65.27 | -12.97 | 21.74 | ||||||||||
| EPS | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 |
DCAL Company Updates
FY 2026FY 2026
Investor Presentation
May 20PDF
Feb 4PDF
Nov 5PDF
+3 more
DCAL Stock Peers
DCAL Past Performance & Peer Comparison
DCAL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dishman Carbogen Amcis Ltd | 31.44 | 0.53 | — |
| Divi's Laboratories Ltd | 86.71 | 13.29 | 0.36% |
| Syngene International Ltd | 51.64 | 3.38 | 0.31% |
| Aarti Pharmalabs Ltd | 35.45 | 3.11 | 0.51% |
DCAL Stock Price Comparison
Compare DCAL with any stock or ETFCompare DCAL with any stock or ETF
DCAL
DCAL Holdings
DCAL Shareholdings
DCAL Promoter Holdings Trend
DCAL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
DCAL Institutional Holdings Trend
DCAL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
DCAL Shareholding Pattern
DCAL Shareholding Pattern
DCAL Shareholding History
DCAL Shareholding History
Foreign Institutions
Mutual Funds Invested in DCAL
Mutual Funds Invested in DCAL
No mutual funds holding trends are available
Top 3 Mutual Funds holding Dishman Carbogen Amcis Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3163% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months 0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/93 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.07% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 92/130 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0001% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 797/1047 (-9) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing DCAL stock
smallcases containing DCAL stock
Looks like this stock is not in any smallcase yet.
DCAL Events
DCAL Events
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
DCAL Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
DCAL has not given any dividends in last 5 years
DCAL Upcoming Dividends
DCAL Upcoming Dividends
No upcoming dividends are available
DCAL Past Dividends
DCAL Past Dividends
Cash Dividend
Ex DateEx DateSep 12, 2019
Final
Final | Div/Share: ₹0.20
Dividend/Share
₹0.20
Ex DateEx Date
Sep 12, 2019
DCAL Stock News & Opinions
DCAL Stock News & Opinions
Articles & Videos
Spotlight
Spotlight
Dishman Carbogen gains after Swiss unit commissions 1,200 kWp solar facilityThe new solar power plant, has installed capacity of 1,200 kWp, comprises a total of 2,448 photovoltaic modules installed on an area of approximately 6,200 square meters of the company's premises. This makes the plant one of the most efficient conventional ground-mounted systems in the Swiss Mittelland and brings its efficiency close to that of vertical alpine installations. Ground-mounted photovoltaic systems remain rare in Switzerland. The project was carried out in collaboration with the company's energy and infrastructure partners IWB (Industrielle Werke Basel) and its subsidiary Planeco, which were responsible for the planning and implementation of the facility. Stephan Fritschi, chief executive officer of CARBOGEN AMCIS, said, 'With the commissioning of this photovoltaic system, we are making a targeted investment in a sustainable and future-oriented energy supply for our site. The project is an important milestone on our path to consistently implementing our environmental goals,' Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India. On consolidated basis, net profit declined 49.55% to Rs 21.74 crore in Q4 FY26, compared with Rs 43.09 crore in Q4 FY25. Revenue from operations jumped 18.85% YoY to Rs 851.40 crore in Q4 FY26.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis EGM scheduledDishman Carbogen Amcis announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 19 June 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Dishman Carbogen Amcis consolidated net profit declines 49.55% in the March 2026 quarterNet profit of Dishman Carbogen Amcis declined 49.55% to Rs 21.74 crore in the quarter ended March 2026 as against Rs 43.09 crore during the previous quarter ended March 2025. Sales rose 18.85% to Rs 851.40 crore in the quarter ended March 2026 as against Rs 716.34 crore during the previous quarter ended March 2025. For the full year,net profit rose 2907.72% to Rs 97.45 crore in the year ended March 2026 as against Rs 3.24 crore during the previous year ended March 2025. Sales rose 8.13% to Rs 2931.90 crore in the year ended March 2026 as against Rs 2711.50 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales851.40716.34 19 2931.902711.50 8 OPM %19.1421.32 -19.2917.29 - PBDT136.07118.54 15 447.39331.16 35 PBT47.2839.45 20 108.7037.42 190 NP21.7443.09 -50 97.453.24 2908 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to announce Quarterly ResultDishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 19 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Dishman Carbogen Amcis reports consolidated net loss of Rs 12.97 crore in the December 2025 quarterNet loss of Dishman Carbogen Amcis reported to Rs 12.97 crore in the quarter ended December 2025 as against net profit of Rs 4.63 crore during the previous quarter ended December 2024. Sales rose 5.49% to Rs 719.80 crore in the quarter ended December 2025 as against Rs 682.34 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales719.80682.34 5 OPM %15.7120.54 - PBDT73.9896.98 -24 PBT-10.4425.01 PL NP-12.974.63 PL Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to declare Quarterly ResultsDishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis allots NCDs aggregating to Rs 50 crDishman Carbogen Amcis has allotted 5,000 Senior, Secured, Rated, Listed, Transferable, Taxable, Redeemable Non-Convertible Debentures of Rs 1 lakh each aggregating to Rs 50 crore on private placement basis on 20 January 2026. Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to convene board meetingDishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 27 December 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Dishman Carbogen Amcis consolidated net profit rises 97.25% in the September 2025 quarterNet profit of Dishman Carbogen Amcis rose 97.25% to Rs 65.27 crore in the quarter ended September 2025 as against Rs 33.09 crore during the previous quarter ended September 2024. Sales declined 17.29% to Rs 652.65 crore in the quarter ended September 2025 as against Rs 789.04 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales652.65789.04 -17 OPM %22.8118.65 - PBDT114.67117.17 -2 PBT30.5445.08 -32 NP65.2733.09 97 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Corporate
Dishman Carbogen Amcis to conduct board meetingDishman Carbogen Amcis will hold a meeting of the Board of Directors of the Company on 4 November 2025.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.9%, vs industry avg of 11.81%
Over the last 5 years, market share decreased from 16.75% to 14.51%